Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The review extension was needed as the FDA required time to review Cytokinetics’ proposed Risk Evaluation and Mitigation Strategy (REMS).

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

HealthDay News — An intensive blood pressure (BP) reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and older with untreated hypertension ...

HealthDay News — For children with sickle cell anemia (SCA), hydroxyurea has sustained clinical benefits in terms of reducing emergency department visits and hospital days, according to a study ...

NIH Director Dr Jay Bhattacharya previously announced plans to develop "national disease registries, including a new one for autism" as part of a larger research effort.

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

The Food and Drug Administration (FDA) has cleared the Jewel ® Patch Wearable Cardioverter Defibrillator (Patch-WCD) for adult patients aged 18 years and older who are at risk for sudden cardiac ...

Increase seen in lifetime use among adults and adolescents; past-year use higher among young adults, older adults.

Measles may reestablish endemicity, with an estimated 851,300 cases over 25 years at current vaccination rates.

Outbreak mainly affected members of communities with low measles vaccination coverage in New Mexico, Oklahoma, and Texas.